Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer
Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Summary
This study is a single-arm, open-label, multicenter phase II clinical trial aimed at evaluating the efficacy, safety, and pharmacokinetics of SHR-1826 in treating locally advanced or metastatic non-small cell lung cancer . The recommended dose of SHR-1826 was administered via intravenous infusion once every 3 weeks (Q3W), with each treatment cycle lasting 21 days until meeting protocol-defined treatment discontinuation criteria.
Official title: A Phase II Clinical Study on the Efficacy, Safety, and Pharmacokinetics of SHR-1826 for Injection in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2026-04
Completion Date
2028-12
Last Updated
2026-03-24
Healthy Volunteers
No
Conditions
Interventions
SHR-1826
SHR-1826
Locations (1)
Affiliated Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China